Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial

BACKGROUND: The value of anti-angiogenesis antibody therapy in recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) remains unknown. We carried out a phase II study to evaluate the addition of bevacizumab to paclitaxel plus carboplatin in R/M NPC. MATERIALS AND METHODS: A total of 80 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, T., Yang, Y., Ma, S., Lin, L., Zhang, C., Ding, X., Wang, R., Feng, G., Chen, Y., Xu, R., Huang, Y., Zhang, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637468/
https://www.ncbi.nlm.nih.gov/pubmed/34837744
http://dx.doi.org/10.1016/j.esmoop.2021.100313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637468/
https://www.ncbi.nlm.nih.gov/pubmed/34837744
http://dx.doi.org/10.1016/j.esmoop.2021.100313

Ejemplares similares